830 Winter Street, 3rd Floor
Waltham, MA 02451, United States
Histogenics Corporation develops and commercializes regenerative medicine products in the musculoskeletal segment of the marketplace. Its product candidate includes NeoCart, which is in Phase III clinical trials, a first-line therapy for full thickness knee chondral lesions in skeletally mature adults age 18 to 55. The company has an exclusive channel collaboration agreement with Intrexon Corporation for the development and commercialization of allogeneic genetically modified chondrocyte cell therapeutics for the treatment or repair of damaged articular hyaline cartilage in humans. Histogenics Corporation was incorporated in 2000 and is headquartered in Waltham, Massachusetts.
Keys to HSGX Profits 1. More than 85 Global and 45 US-Owned Patents and Licenses + Ability to Survive Credible Patent Challenges:
Robust Intellectual Property covers cell culture, bioreactors and materials. Provides broad coverage for methods in cartilage production and tissue sciences. Coverage through 2031. 2. Real & Strategic Partners:
Take breakthroughs globally with the flip of a switch. Advanced Regenerative Manufacturing Institute(ARMI)
, Brigham and Women's Hospital
, Cornell University
, Harvard University
, Lonnie Shea, Ph.D., University of Michigan
, Shuichi Mizuno, Ph.D.
, Dr. R. Lane Smith, Stanford U
., Jennifer Elisseeff, Ph.D., Johns Hopkins Medicine
, plus others on the Scientific Advisory Board
. 3. Leadership: Management
and Board of Directors
plus Scientific Advisory Board
(7 which includes 2000 co-founder, Dr. Shuichi Mizuno). 4. Block Owners: Low Average Turnover Rating
. HSGX $9.3m mkt cap
[@0.14 pps x 66.7m O/S = $9.3m]. 5. HSGX's NeoCart Platform
alike VCEL's MACI
cartilage repair. $710m mkt cap
[@16.60 pps x 42.7m O/S = $710m]. 52-wk high-low $17.51 - $3.63.
ONE Stop: Sites on HSGX(plus other stocks)
Free Real-Time Quotes/Level II (BATS Order Book): lower left of the homepage.